LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) (‘Poolbeg’ or the ‘Firm’), a medical stage infectious illness pharmaceutical firm with a singular capital mild medical mannequin, has appointed Singer Capital Markets as Joint Dealer with instant impact. finnCap Ltd will proceed to behave as Nominated Adviser and Joint Dealer alongside J&E Davy as further Joint Dealer.
– Ends –
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O’Connell, CFO
+44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint Dealer)
Geoff Nash, James Thompson, Charlie Beeson
Richard Chambers, Sunila de Silva (ECM), Nigel Birks
+44 (0) 207 220 0500
J&E Davy (Joint Dealer)
Anthony Farrell, Niall Gilchrist
+353 (0) 1 679 6363
Singer Capital Markets (Joint Dealer)
Phil Davies, Sam Butcher
+44 (0)20 7496 3000
Melanie Toyne Sewell, Rozi Morris, Tim Area
+44 (0) 20 7457 2020
About Poolbeg Pharma
Poolbeg Pharma is a medical stage infectious illness pharmaceutical firm, with a capital mild medical mannequin which goals to develop a number of merchandise sooner and extra affordably than the standard biotech mannequin. The Firm, headquartered in London, is led by a group with a observe document of creation and supply of shareholder worth and aspires to change into a “one-stop store” for Huge Pharma searching for mid-stage merchandise to license or purchase.
The Firm is concentrating on the rising infectious illness market. Within the wake of the COVID-19 pandemic, infectious illness has change into one of many quickest rising pharma markets and is anticipated to exceed $250bn by 2025.
With its preliminary belongings from Open Orphan plc, an trade main infectious illness and human problem trials enterprise, Poolbeg has entry to data, expertise, and medical information from over 20 years of human problem trials. The Firm is utilizing these insights to accumulate new belongings in addition to reposition medical stage merchandise, lowering spend and danger. Amongst its portfolio of thrilling belongings, Poolbeg has a small molecule immunomodulator for extreme influenza (POLB 001) which has commenced its LPS human problem trial with outcomes anticipated by 12 months finish 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The Firm can be growing an oral vaccine supply platform and is progressing two synthetic intelligence (AI) drug discovery programmes to speed up the ability of its human problem mannequin information and biobank, with outcomes from the primary programme anticipated in This autumn 2022.
For extra info, please go to www.poolbegpharma.com or observe us on LinkedIn and Twitter @PoolbegPharma.
This info is offered by RNS, the information service of the London Inventory Change. RNS is accepted by the Monetary Conduct Authority to behave as a Major Data Supplier in the UK. Phrases and circumstances referring to the use and distribution of this info might apply. For additional info, please contact [email protected] or go to www.rns.com.
SOURCE: Poolbeg Pharma PLC
View supply model on accesswire.com: